Publications (25) Miguel Alcoceba Sánchez publications

filter_list Cancer Research

2025

  1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)

    Medicina Clinica

2024

  1. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

2023

  1. Characterization of Three Somatic Mutations in the 3′UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia

    Cells, Vol. 12, Núm. 23

  2. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

2022

  1. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

    Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773

  2. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

    Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671

  3. Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

    Molecular Cancer, Vol. 21, Núm. 1

  4. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction

    Frontiers in Immunology, Vol. 13

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome

    Frontiers in Oncology, Vol. 11

2020

  1. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863

2018

  1. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

    PLoS ONE, Vol. 13, Núm. 6

  2. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome

    Haematologica, Vol. 103, Núm. 7, pp. 1198-1208

  3. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2017

  1. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

  2. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152

2016

  1. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion

    Leukemia Research, Vol. 46, pp. 30-36

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  2. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  3. Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia

    BioMed Research International, Vol. 2014